瑞科生物-B(02179)发盈警预期中期股东应占亏损2.01-2.22亿元同比收窄约34.71%至40.93%

智通财经07-31

智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2655354828?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-31 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655354828","market":"hk","top_or_hot":-1,"title":"瑞科生物-B(02179)发盈警 预期中期股东应占亏损2.01-2.22亿元 同比收窄约34.71%至40.93%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1474663.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞科生物-B(02179)发盈警 预期中期股东应占亏损2.01-2.22亿元 同比收窄约34.71%至40.93%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞科生物-B(02179)发盈警 预期中期股东应占亏损2.01-2.22亿元 同比收窄约34.71%至40.93%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1474663.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1474663.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02179","symbol_name":"瑞科生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1474663.html","article_id":"2655354828","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655354828","pubTimestamp":1785490009,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落。与此同时，因上年同期本公司确认了一笔知识产权对外授权许可收入，报告期内，同类授权业务正在推进中但尚未满足收入确认条件，报告期内收入同比有所下降。整体而言，亏损呈收窄趋势，但仍有待进一步改善。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02179":"瑞科生物-B","BK1161":"生物科技"},"translate_title":"Ruike Bio-B (02179) issued a profit warning and expected the interim loss attributable to shareholders to be 201-222 million yuan, narrowing by approximately 34.71% year-on-year to 40.93%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02179":1.5},"content_text":"智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落。与此同时，因上年同期本公司确认了一笔知识产权对外授权许可收入，报告期内，同类授权业务正在推进中但尚未满足收入确认条件，报告期内收入同比有所下降。整体而言，亏损呈收窄趋势，但仍有待进一步改善。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655354828","isCrawlerRequest":true}

瑞科生物-B(02179)发盈警 预期中期股东应占亏损2.01-2.22亿元 同比收窄约34.71%至40.93%

精彩评论

瑞科生物-B(02179)发盈警预期中期股东应占亏损2.01-2.22亿元同比收窄约34.71%至40.93%